Anthem Biosciences delivered a stellar Q4FY26, marking its highest-ever revenue quarter!

Full-year FY26 revenue grew 15% YoY to ₹2,124.3 Cr, with Q4 alone soaring 26% YoY to ₹610.9 Cr.

Profitability surged, with FY26 EBITDA up 30.8% to ₹989.6 Cr (43.4% margin) and PAT up 31.1% to ₹591.8 Cr (26.0% margin). Q4 EBITDA hit ₹318.4 Cr (48.1% margin) & PAT ₹189.8 Cr (28.7% margin). The CRDMO segment was a major growth engine, contributing over 83% of revenues and growing 17.7% YoY for the full year.

Strategic focus remains on building an agile, science-led, and future-ready CRDMO platform globally.

Key developments include the ongoing construction of Unit IV, a new Greenfield facility, with Phase I seeing a ₹1,200 Cr investment to boost custom synthesis (365 KL) and fermentation (100 KL) capacities.

Net cash stood strong at ₹1,374.3 Cr as of March 31, 2026. Management is committed to sustainable growth and expanding profitability across all business segments.